


**Compsns. for contraception or treatment of gynaecological disorders****Publication number:** DE3051166 (C2)**Publication date:** 1990-10-18**Cited documents:****Inventor(s):** ELGER, WALTER, DR. ; BEIER, SYBILLE, DIPL.-BIOL. DR. ;  
VARCHMIN, GERDA, DR. ; SCHILLINGER, EKKEHARD, DR.,  
1000 BERLIN, DE DE2652761 (A1)**Applicant(s):** SCHERING AG, 1000 BERLIN UND 4709 BERGKAMEN, DE**Classification:****- international:** **A61K31/585; A61K31/58;** (IPC1-7): A61K31/58; A61K31/585**- European:** A61K31/585; A61K31/585**Application number:** DE19803051166 19800611**Priority number(s):** DE19803051166 19800611; DE19803022337 19800611Abstract of **DE 3051166 (C2)**

New prepn. for contraception and for the treatment of gynaecological disorders are based on 6 beta, 7 beta, 15 beta, 16 beta-dimethylene -3-oxo-4-androstene/17 (beta-1')-spiro-5' /-perhydrofuran-2'-one (I). (I) (a known aldosterone-antagonist diuretic) has been found to display marked gestagenic activity, as shown by its positive effects in a modified Clauberg test in rabbits at dosages of 0.1-1.0 mg s.c. It may be used alone or in combination with an oestrogen as a contraceptive agent, esp. in women suffering from high blood pressure or in whom oral contraceptives cause hypertension. (I) may also be used for the treatment of premenstrual disorders. It is similar to progesterone in its combination of geotagenic and anti-mineralocorticoid properties, with the advantage of oral activity

.....  
Data supplied from the **esp@cenet** database — Worldwide